Thrombophilias and gynaecology.
In gynaecology, women are exposed to sex steroids when using oral contraceptives, hormone replacement therapy or when undergoing in vitro fertilization treatment and ovulation induction. Oral contraceptives and the use of hormone replacement therapy increase the risk of venous thrombosis. The risk is highest in the first year of use and higher among women with clotting defects. Women taking third-generation oral contraceptives have an almost twofold increased risk of venous thrombosis compared with those taking second-generation oral contraceptives. Inherited clotting defects, which are themselves risk factors of venous thrombosis, (e.g. factor V Leiden mutation, deficiency of protein C, protein S or antithrombin, high plasma levels of factor VIII, and prothrombin mutation) appear synergistically increase the risk of venous thrombosis caused by oral contraceptives. Recent studies also point to an interaction between hormone replacement therapy and coagulation defects in causing venous thrombosis. Emerging studies show that in vitro fertilization treatment and ovulation induction are also risk factors for venous thrombosis; the role of coagulation defects in this association is not yet clear.
Bloemenkamp
Kitty W M
KW
Department of Obstetrics, Gynaecology and Reproductive Medicine, Leiden University Medical Center, P.O. Box 9600, RC 2300, Leiden, The Netherlands. kwm.bloememkamp@planet.nl
Helmerhorst
Frans M
FM
Rosendaal
Frits R
FR
Vandenbroucke
Jan P
JP
D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects; D006801:Humans; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications*; D020246:Venous Thrombosis / Q000209:etiology*
D003278:Contraceptives, Oral, Hormonal